Examination for the effect of combination therapy with raloxifene and eldecalcitol in primary osteoporotic patients -Switch from alfacalcidol to eldecalcitol
Not Applicable
Recruiting
- Conditions
- Osteoporosis
- Registration Number
- JPRN-UMIN000007742
- Lead Sponsor
- Kyorin University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 120
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who are diagnosed as contraindication of raloxifene treatments 2) Patients who are diagnosed as contraindication of eldecalcitol treatments 3) Patients who have serum calcium levels of above 10.5mg/dL 4) Patients who have taken osteoporosis treatments other than raloxifene and alfacalcidol 5) Patients who are inappropriate for this study by physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of lumbar spine bone mineral density
- Secondary Outcome Measures
Name Time Method Change of total hip bone mineral density Number of fracture occurred Change of bone metabolic markers Safety